Table 8.
Myelosuppression after ruxolitinib treatment.
| Subgroup | Total | Adults | Children | |||
|---|---|---|---|---|---|---|
| Cumulative incidence | 95% CI | Cumulative incidence | 95% CI | Cumulative incidence | 95% CI | |
| SR-aGVHD | ||||||
| Cytopenia | ||||||
| Grades I–IV | 53.2 | 16.0–90.4 | 37.3 | 0.0–82.1 | 53.8 | NA |
| Grades III–IV | 31.0 | 0.0–100.0 | 16.5 | 0.0–100.0 | NA | NA |
| Anemia | ||||||
| Grades I–IV | 45.6 | 19.8–71.5 | 24.7 | 0.0–55.3 | 25.0 | NA |
| Grades III–IV | 37.3 | 18.4–56.3 | 26.0 | 7.0-45.0 | 25.0 | NA |
| Leukopenia | ||||||
| Grades I–IV | 44.2 | 24.4–64.0 | 34.3 | 0.6–68.1 | 26.0 | 0.0–100.0 |
| Grades III–IV | 36.8 | 20.7–52.9 | 28.0 | 14.8–41.2 | 26.0 | 0.0–100.0 |
| Thrombocytopenia | ||||||
| Grades I–IV | 40.6 | 21.4–59.8 | 23.7 | 0.0–56.7 | 19.8 | 0.0–41.8 |
| Grades III–IV | 42.4 | 25.0–59.7 | 31.0 | 0.0–73.2 | 30.5 | 0.0–100.0 |
| SR-cGVHD | ||||||
| Cytopenia | ||||||
| Grades I–IV | 28.8 | 13.0–44.6 | 28.3 | 4.8–51.7 | NA | NA |
| Grades III–IV | 10.4 | 0.0–27.9 | 21.0 | 0.0–100.0 | NA | NA |
| Anemia | ||||||
| Grades I–IV | 35.1 | 13.2–57.0 | 20.7 | 0.0–57.9 | 8.3 | NA |
| Grades III–IV | 11.2 | 2.1–20.3 | 5.0 | 0.0–15.6 | 0.0 | NA |
| Leukopenia | ||||||
| Grades I–IV | 22.9 | 6.2–39.6 | 11.5 | 2.6–20.4 | 8.3 | NA |
| Grades III–IV | 8.9 | 4.7–13.1 | 9.8 | 2.3–17.3 | 0.0 | NA |
| Thrombocytopenia | ||||||
| Grades I–IV | 19.2 | 6.9–31.6 | 7.0 | 0.0–17.6 | 8.3 | NA |
| Grades III–IV | 10.2 | 3.6–16.8 | 3.8 | 0.0–8.3 | 0.0 | NA |
CI, confidence interval; NA, not available; SR-aGVHD, steroid-refractory acute graft-versus-host disease; SR-cGVHD, steroid-refractory chronic graft-versus-host disease.